Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 18/20 | 0.67 |
| ▸ | HDAC2 | Q92769 | 15/20 | 0.65 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21275918 | 0.91 | HDAC3 (0.64) | HDAC3HDAC2HDAC1KCNH2 | |
| SCHEMBL20181706 | 0.86 | HDAC3 (0.74) | HDAC3HDAC2HDAC1KCNH2 | |
| SCHEMBL20181694 | 0.82 | HDAC3 (1.00) | HDAC3HDAC2HDAC1KCNH2 | |
| SCHEMBL20181670 | 0.81 | HDAC2 (1.00) | HDAC3HDAC2HDAC1KCNH2 | |
| SCHEMBL20181703 | 0.81 | HDAC2 (0.69) | HDAC3HDAC2HDAC1KCNH2 | |
| SCHEMBL20181531 | 0.78 | HDAC3 (0.74) | HDAC3HDAC2HDAC1KCNH2 | |
| SCHEMBL21275926 | 0.77 | HDAC3 (0.72) | HDAC3HDAC2HDAC1KCNH2 | |
| SCHEMBL20181527 | 0.76 | HDAC3 (0.68) | HDAC3HDAC2HDAC1KCNH2 | |
| SCHEMBL20181845 | 0.73 | KCNH2 (0.66) | HDAC3HDAC2HDAC1KCNH2 | |
| SCHEMBL20181474 | 0.72 | HDAC2 (0.80) | HDAC3HDAC2HDAC1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180141923-A1 | SELECTIVE HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141923-A1 | SELECTIVE HDAC1,2 INHIBITORS | HDAC1, HDAC2, HDAC11 | HDAC3 6/4885HDAC2 2/4885HDAC1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.